Cart
sales@molnova.com
Deferasirox (Fe3+ chelate)
CAS No. 554435-83-5
Deferasirox (Fe3+ chelate)( —— )
Catalog No. M33211 CAS No. 554435-83-5
Deferasirox (Fe3+ chelate) is an orally available iron chelator with potential anticancer activity, inhibits the anti-apoptotic activity of MCL-1, and can be used to study iron overload.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 93 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDeferasirox (Fe3+ chelate)
-
NoteResearch use only, not for human use.
-
Brief DescriptionDeferasirox (Fe3+ chelate) is an orally available iron chelator with potential anticancer activity, inhibits the anti-apoptotic activity of MCL-1, and can be used to study iron overload.
-
DescriptionDeferasirox Fe3+ Chelate is an iron chelating agent extracted from patent WO2003053986.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number554435-83-5
-
Formula Weight426.18
-
Molecular FormulaC21H12FeN3O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (117.32 mM; Ultrasonic )
-
SMILESO=C([O-])C1=CC=C(C=C1)N2N=C3C=4C=CC=CC4[O-][Fe+3]5[O-]C=6C=CC=CC6C2=[N]35
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. WO2003053986
molnova catalog
related products
-
(R)-Isomucronulatol
(R)-Isomucronulatol (2H-1-Benzopyran-7-ol), a flavonoid that can be extracted from the leaves of Astragalus membranaceus, Sophora japonica, Sclerotium tigrinum, and Glycyrrhiza glabra, inhibits the proliferation and apoptosis of BMSCs in the TNF-α microenvironment.
-
Bromelain
Bromelain is an anti-inflammatory drug derived from pineapple stem.
-
TAS6417
TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC.
